Amarin Corp Plc (AMRN)

[lettruthringout]

Shouldn't take long for sales in U.K.

What is the process for securing reimbursement for a new pharmaceutical product?

As noted above, the NHS funds treatments in a number of different ways. This means there is no single pathway to securing NHS reimbursement for a new product. Nonetheless, NICE is often considered the gatekeeper to reimbursement, because a positive recommendation for a product or treatment from NICE obliges the NHS to make funding available for it, usually within three months of the recommendation.

https://www.cov.com/-/media/files/corporate/publications/2020/08/united-kingdom.pdf

NICE’s Standard Assessment Methodology
For most conventional products, NICE will issue a positive recommendation if it assesses a product to have an ICER, usually against an existing reference, of less than £20,000. NICE may apply its discretion to recommend technologies with ICERs between £20,000 and £30,000, where justified on certain grounds, such as the innovative nature of a drug.

U.S. ICER issues positive recommendation for Vascepa

https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-additive-cardiovascular-disease-therapies/